A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system. The registry will primarily assess the rate of MACE (cardiac death, myocardial infarction and clinically driven target lesion revascularization.
Study Type
OBSERVATIONAL
Enrollment
1,027
COBRA PzF Coronary Stent System
Clinique Axium
Aix, France
GCS Cardio
Annecy, France
SCM Angioscan
Antony, France
Clinique La Casamance
Aubagne, France
Centre Hospitalier
Avignon, France
Clinique La Fourcade
Bayonne, France
Centre Hospitalier
Brivé, France
Clinique des Domes
Clermont, France
Clinique Cardiologie
Évecquemont, France
Clinique Mutualiste
Grenoble, France
...and 8 more locations
MACE
Composite clinical endpoint of cardiac death, myocardial infarction, and clinically driven target lesion revascularization
Time frame: 12 months
Stent thrombosis
Stent thrombosis (according to ARC definition)
Time frame: 12 months
TVR and TLR
Target vessel and lesion revascularization
Time frame: 12 months
DAPT
Mean length of dual antiplatelet therapy
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.